MétaCan
Menu
Back to cohort
Record W2156520838 · doi:10.1158/1078-0432.ccr-09-1993

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

2010· review· en· W2156520838 on OpenAlexaff
Patricia LoRusso, Scott A. Boerner, Lesley Seymour

Bibliographic record

VenueClinical Cancer Research · 2010
Typereview
Languageen
FieldMathematics
TopicStatistical Methods in Clinical Trials
Canadian institutionsQueen's University
Fundersnot available
KeywordsClinical trialClinical study designMedicineDrug developmentResearch designClinical endpointMedical physicsDrugPharmacologyPathology

Abstract

fetched live from OpenAlex

Phase I clinical trials represent the first step in bringing promising new treatments from the laboratory to the clinic. Although the importance of phase I clinical trials is widely recognized, there is currently no consensus among the scientific, medical, and statistical communities on how best to do these studies in humans. With the advent of targeted therapies, it has become evident that we need to tailor the design of phase I studies for the particular drug class under investigation and any endpoints that are being defined. The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides broad external scientific and clinical input on the design and prioritization of early-phase clinical trials with agents for which the NCI Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application through the U.S. Food and Drug Administration (FDA). The IDSC has formed a number of task forces and working groups, including the Clinical Trial Design Task Force and the Biomarker Working Group, many with membership from within the IDSC as well as external experts, including participants from academia, the pharmaceutical industry, and regulatory authorities. The Clinical Trials Design Taskforce sponsored a Phase I Workshop with the primary goal being to develop consensus recommendations for the optimal design of phase I studies. The primary focus included (1) efficient trial designs, (2) phase I drug combinations, and (3) appropriate statistical and correlative endpoints. In this CCR Focus series, articles summarize key aspects and recommendations on phase I studies (including combination trials), such as design, use of biomarkers, the European Union and Japanese perspectives on design, requirements for first-in-human and other phase I studies, and ensuring regulatory and International Conference on Harmonization (ICH) compliance. A final article summarizes recommendations for the design and conduct of phase II studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Direct model labels (unvalidated)

Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.

Model armCategoriesStudy designConfidence
gemmano category
Domain: not available · Genre: Review
About the Canadian research system: no · About a Canadian topic: no
Not applicablehigh
gptMetaresearch
Domain: Methods · Genre: Review
About the Canadian research system: no · About a Canadian topic: no
Other designhigh
models splitAgreement compares identical category sets and study designs across arms.

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.054
metaresearch head score (Gemma)0.060
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.946
Threshold uncertainty score0.286

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0540.060
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0070.006
Science and technology studies0.0010.003
Scholarly communication0.0070.007
Open science0.0040.003
Research integrity0.0050.009
Insufficient payload (model declined to judge)0.0070.007

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.993
GPT teacher head0.854
Teacher spread0.138 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Labeled directly by 2 models reading the full record.

Metaresearch

The models disagree on parts of this classification; every voice is preserved in the section at the end of the page.

Study designNot applicable · Other design
DomainMethods
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations118
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicStatistical Methods in Clinical TrialsCategoryMetaresearchFrench-language works237,207